AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9534832
Drug: Paroxetine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine (20 mg daily) for 8 weeks in depressed patients
Trial: 202906
Drug: Polyc chemotherapy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyc chemotherapy, high-dosage vitamin-A treatment, Endoxan, immunotherapy, and proteolytic enzymes in 5 combinations of therapy
Trial: 16948122
Drug: Postoperative interferon‐α
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative interferon‐α therapy (Group 1)
Trial: 16948122
Drug: No postoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No postoperative interferon‐α therapy (Group 2)
Trial: 11318053
Drug: Unintentional contributions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unintentional contributions to nonspecific preparation
Trial: 9135342
Drug: 20 ml
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ml of 0.5% bupivacaine
Trial: 7931470
Drug: High-dose etoposide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose etoposide and cisplatin (EP)
Trial: 7931470
Drug: Standard-dose etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard-dose etoposide and cisplatin (EP)
Trial: 7931470
Drug: Nonrandomized standard-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonrandomized standard-dose therapy
Trial: 2902738
Drug: CQP 201-403
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CQP 201-403 (0.01 mg)
Trial: 2902738
Drug: CQP 201-403
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CQP 201-403 (0.02 mg)
Trial: 2902738
Drug: CQP 201-403
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CQP 201-403 (0.03 mg)
Trial: 30645844
Drug: Yiqi Huaju
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yiqi Huaju Recipe (YHR) + routine Western drugs
Trial: 30645844
Drug: placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo + routine Western drugs
Trial: 26603252
Drug: Iron pyrophosphate
RxNorm normalized name: prenatal vitamins no.113/iron pyrophosphate/levomefolate 4.5 mg iron-1 mg ORAL TABLET,CHEWABLE
DrugBank: Ferric pyrophosphate (DB09147)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron pyrophosphate (approximately 1 mg/kg) daily until 9 months of age
Trial: 26603252
Drug: Placebo daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo daily until 9 months of age
Trial: 20946752
Drug: Standard individual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard individual cognitive behavioral therapy (CBT) for alcohol use disorders
Trial: 20946752
Drug: Alcohol behavioral
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol behavioral couple therapy
Trial: 20946752
Drug: Blended individual
RxNorm normalized name: Io-Blend
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blended individual CBT and alcohol behavioral couple therapy
Trial: 15246968
Drug: 0.1 mg
RxNorm normalized name: biotin 0.1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg oral solution of GI181771X
Trial: 15246968
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg oral solution of GI181771X
Trial: 15246968
Drug: 1.5 mg
RxNorm normalized name: boron 1.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg oral solution of GI181771X
Trial: 15246968
Drug: 5.0 mg
RxNorm normalized name: RUXOLITINIB 5.0 mg ORAL TABLET [JAKAFI]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.0 mg tablet of GI181771X
Trial: 11167667
Drug: Inogatran (thrombin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inogatran (thrombin inhibitor) administered intravenously; specific dosage and duration not mentioned.
Trial: 9626201
Drug: Pamidronate (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamidronate (90 mg intravenously every 3 to 4 weeks)
Trial: 7881452
Drug: Analgesic plus
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Analgesic plus caffeine (C)
Trial: 7881452
Drug: Analgesic alone
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Analgesic alone (A)
Trial: 3295599
Drug: Defibrotide (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Defibrotide (400 mg b.i.d. by IV route)
Trial: 3295599
Drug: Calcium heparin
RxNorm normalized name: HEPARIN CALCIUM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium heparin (5000 I.U. t.i.d. s.c.)
Trial: 3295599
Drug: Defibrotide and
RxNorm normalized name: defibrotide
DrugBank: Defibrotide (DB04932)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Defibrotide and Calcium heparin
Trial: 30072191
Drug: Nab-paclitaxel (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nab-paclitaxel (100 mg/m2)
Trial: 3664330
Drug: Ketoconazole (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoconazole (200 mg twice daily)
Trial: 26739683
Drug: Verapamil (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (80 mg three times daily)
Trial: 26739683
Drug: Rifampicin (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampicin (600 mg once daily)
Trial: 9165323
Drug: 200 ml
RxNorm normalized name: Bag Top-Fill, 1200 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 ml of full fat milk
Trial: 9165323
Drug: 200 ml
RxNorm normalized name: Bag Top-Fill, 1200 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 ml of still mineral water
Trial: 7956714
Drug: Pentoxifylline (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (300 mg/day)
Trial: 3658570
Drug: Taurine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taurine (30 mg/kg/d)
Trial: 23601143
Drug: Intravenous antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous antibiotics therapy (IVAT) for exacerbation, duration: 14 days.
Trial: 19325192
Drug: Nicorandil treatment
RxNorm normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicorandil treatment
Trial: 16340944
Drug: High-protein diet
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-protein diet (1.9 g/kg BW)
Trial: 16340944
Drug: Normal-protein diet
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal-protein diet (1.3 g/kg BW)
Trial: 21423028
Drug: Irbesartan (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan (300 mg/d)
Trial: 11130772
Drug: cilazapril (C),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cilazapril (C), 2.5 mg once daily
Trial: 16195905
Drug: Oral nystatin
RxNorm normalized name: Nystatin
DrugBank: Nystatin (DB00646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral nystatin (3x10(6) U per day)
Trial: 12860576
Drug: Eplerenone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eplerenone (50 mg/d, titrated to max 200 mg)
Trial: 12860576
Drug: Amlodipine (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (2.5 mg/d, titrated to max 10 mg)
Trial: 10583711
Drug: Deoxycholic acid
RxNorm normalized name: Deoxycholic Acid
DrugBank: Deoxycholic acid (DB03619)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Deoxycholic acid (DCA) 750 mg day‐1 for 3 weeks
Trial: 9522686
Drug: Control group:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group: prepared surfaces were left unprotected after preparation
Trial: 2060527
Drug: Pyrimethamine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyrimethamine (50 mg/day) plus Clindamycin (2.4 g/day)
Trial: 2060527
Drug: Pyrimethamine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyrimethamine (50 mg/day) and Sulfadiazine (4.0 g/day)
Trial: 6416698
Drug: oral pyridoxine
RxNorm normalized name: pyridoxine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral pyridoxine
Trial: 31755526
Drug: Chimeric Yellow
RxNorm normalized name: yellow OB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chimeric Yellow Fever Derived Tetravalent Dengue Vaccine (CYD‐TDV) on an accelerated dosing schedule (months 0, 2, and 6)
Trial: 31755526
Drug: Chimeric Yellow
RxNorm normalized name: yellow OB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chimeric Yellow Fever Derived Tetravalent Dengue Vaccine (CYD‐TDV) given concurrently with Japanese encephalitis (JE) vaccine
Trial: 31755526
Drug: Chimeric Yellow
RxNorm normalized name: yellow OB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chimeric Yellow Fever Derived Tetravalent Dengue Vaccine (CYD‐TDV)
Trial: 22284441
Drug: Baseline eGFR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline eGFR > 40 mL/min/1.73 m2 and urine protein‐creatinine ratio < 0.22 g/g
Trial: 15126520
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) treatment at 0.0125 mg/kg.d, increased to 0.025 mg/kg.d as tolerated, or decreased to 0.00625 mg/kg.d for 12 months
Trial: 8036820
Drug: Intradermal hepatitis
RxNorm normalized name: hepatitis nosodes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal hepatitis A vaccine (0.1 ml each, three doses)
Trial: 8036820
Drug: Intramuscular hepatitis
RxNorm normalized name: hepatitis nosodes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular hepatitis A vaccine (control group)
Trial: 2659740
Drug: VMCP chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VMCP chemotherapy alone
Trial: 26050967
Drug: V0162 (1600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: V0162 (1600 μg)
Trial: 23456567
Drug: Non-aspirin antiplatelets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-aspirin antiplatelets
Trial: 23456567
Drug: Intravenous tissue
RxNorm normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous tissue plasminogen activator therapy (IV-tPA)
Trial: 21480976
Drug: Topical phenytoin
RxNorm normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical phenytoin dressing
Trial: 18049795
Drug: Clopidogrel 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 600 mg (Group B)
Trial: 18049795
Drug: Clopidogrel 300
RxNorm normalized name: clopidogrel 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 300 mg plus tirofiban (Group C)
Trial: 12755777
Drug: Immediately loaded
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediately loaded FRIALIT-2(R) implants
Trial: 12755777
Drug: Non-loaded implants
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-loaded implants
Trial: 8797143
Drug: Irbesartan 10
RxNorm normalized name: Irbesartan
DrugBank: Irbesartan (DB01029)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Irbesartan 10 mg and above
Trial: 8797143
Drug: Irbesartan (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan (various doses: 1, 5, 10, 25, 50, and 100 mg)
Trial: 1480537
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg trandolapril
Trial: 29696916
Drug: Lotensin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lotensin (10 mg, once a day)
Trial: 27170340
Drug: Basiliximab (IL2Ra)
RxNorm normalized name: Basiliximab
DrugBank: Basiliximab (DB00074)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Basiliximab (IL2Ra) 20 mg on Day 0 and Day 4
Trial: 27170340
Drug: Rabbit antithymocyte
RxNorm normalized name: Rabbit antithymocyte globulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabbit antithymocyte globulin (rATG) 1.0 mg/kg/day from Day 0 to Day 4
Trial: 24124716
Drug: Furosemide 5-40
RxNorm normalized name: furosemide 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide 5-40 mg injection in standard group (CVP < 8 mm Hg)
Trial: 18194332
Drug: Mouthwash and
RxNorm normalized name: SODIUM FLUORIDE 2.4 mg in 1 g DENTAL GEL, DENTIFRICE [AIM TARTAR CONTROL Plus Mouthwash and Whitening]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mouthwash and oral gel containing lactoperoxidase, lactoferrin, and lysozyme
Trial: 16600923
Drug: Dairy products
RxNorm normalized name: Food - Dairy Products, Whey, Cow's Milk
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dairy products enriched with cis-9,trans-11 CLA (1.421 g/d)
Trial: 16600923
Drug: Control dairy
RxNorm normalized name: Beano Dairy Defense
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control dairy products (0.151 g/d CLA)
Trial: 9348572
Drug: Pelvic radiation
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pelvic radiation therapy plus fluorouracil (5-FU)-based chemotherapy
Trial: 9348572
Drug: Pre- and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre- and postoperative bolus 5-FU/leucovorin combined-modality therapy
Trial: 9348572
Drug: Tegafur and
RxNorm normalized name: Tegafur and uracil only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tegafur and uracil (UFT) with oral leucovorin plus pre- or postoperative radiation therapy
Trial: 8446442
Drug: Lidocaine (10‐16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (10‐16 mg)
Trial: 23161117
Drug: Radiotherapy (with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy (with or without chemotherapy)
Trial: 19080093
Drug: Alprostadil (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprostadil (10 ng/ml added into the prime solution and continuous pump infusion of 10 ng/kg/min via central vein until the end of operation)
Trial: 19080093
Drug: Ulinastatin (20,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ulinastatin (20,000 U/kg divided into several doses added into the prime solution)
Trial: 19080093
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Alprostadil and Ulinastatin (according to the above protocols)
Trial: 14570791
Drug: Bupivacaine 8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 8 mg + sufentanil 2.5 microg
Trial: 14570791
Drug: Levobupivacaine 8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levobupivacaine 8 mg + sufentanil 2.5 microg
Trial: 14570791
Drug: Ropivacaine 12
RxNorm normalized name: CLONIDINE 0.04MG/KETOROLAC 15MG/ROPIVACAINE 123MG/50ML INJ SYRIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 12 mg + sufentanil 2.5 microg
Trial: 1403459
Drug: Oral gentamicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral gentamicin
Trial: 29275332
Drug: Bimekizumab (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bimekizumab (240 mg/160 mg/160 mg; 80 mg/40 mg/40 mg; 160 mg/80 mg/80 mg and 560 mg/320 mg/320 mg)
Trial: 11740317
Drug: LAIV (live
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LAIV (live attenuated influenza vaccine)
Trial: 23210417
Drug: Control chewing
RxNorm normalized name: Chewing Gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control chewing gum (sugar-free, without active agents)
Trial: 15837660
Drug: Cryoanalgesia (L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cryoanalgesia (L group, n=20)
Trial: 28933798
Drug: Warfarin 10
RxNorm normalized name: warfarin 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin 10 mg
Trial: 11452703
Drug: Warfarin 10
RxNorm normalized name: warfarin 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin 10 mg plus Vitamin K 10 mg
Trial: 9610586
Drug: Microwave treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microwave treatment (n = 125)
Trial: 9610586
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment (n = 44)
Trial: 7528584
Drug: HHES (hypertonic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HHES (hypertonic saline hydroxyethyl starch solution) 4 ml.kg‐1
Trial: 3228576
Drug: Controlled-release (CR)
RxNorm normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Controlled-release (CR) albuterol 8 mg tablet every 12 h for 8 days
Trial: 3228576
Drug: Immediate-release (IR)
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release (IR) albuterol 4 mg tablet every 6 h for 8 days
Trial: 3228576
Drug: Controlled-release (CR)
RxNorm normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Controlled-release (CR) albuterol
Trial: 30716933
Drug: Low-alcohol orange
RxNorm normalized name: Orange
DrugBank: Orange (DB10549)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-alcohol orange beverage (500 mL/day for 2 weeks)
Trial: 25784207
Drug: CVC placement
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CVC placement in patients with PLT count above 50×10^9/L (group B, 42 patients)
Trial: 19395686
Drug: Minimal-contact behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimal-contact behavioral treatment (n = 392)
Trial: 10023791
Drug: Salmeterol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol (2 puffs: 42 mcg BID)
Trial: 10023791
Drug: Albuterol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol (2 puffs, 180 mcg QID)
Trial: 10023791
Drug: Salmeterol (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol (4 puffs: 84 mcg BID)
Trial: 10023791
Drug: Albuterol (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol (4 puffs, 360 mcg BID)
Trial: 2829267
Drug: ZK 93,426
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZK 93,426 (0.04 mg/kg)
Trial: 2325251
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine 3mg in 10ml of saline solution with epinephrine 50 micrograms added
Trial: 2325251
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine 3mg in 10ml of saline solution without epinephrine
Trial: 30912701
Drug: Alcohol (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (0.5 g L−1)
Trial: 30912701
Drug: Alcohol (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (1.0 g L−1)
Trial: 23708322
Drug: Myo-inositol (1.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myo-inositol (1.1 g) plus D-chiro-inositol (27.6 mg)
Trial: 23708322
Drug: D-chiro-inositol (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-chiro-inositol (500 mg)
Trial: 14985687
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg folic acid combined with 0.25 mg vitamin B12 (n=9)
Trial: 14985687
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg vitamin B6 (n=8)
Trial: 14985687
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg vitamin B6 (n=9)
Trial: 14985687
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg vitamin B6 (n=8)
Trial: 11583721
Drug: Simvastatin 5-10
RxNorm normalized name: simvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 5-10 mg/day for 6 months
Trial: 9711804
Drug: Intramuscular rabies
RxNorm normalized name: rabies virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular rabies vaccine (conventional regimen)
Trial: 9711804
Drug: Intradermal rabies
RxNorm normalized name: rabies virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal rabies vaccine (Thai Red Cross schedule)
Trial: 9711804
Drug: Intramuscular rabies
RxNorm normalized name: rabies virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular rabies vaccine with human or equine rabies immune globulin
Trial: 9711804
Drug: Intradermal rabies
RxNorm normalized name: rabies virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal rabies vaccine with human or equine rabies immune globulin
Trial: 2646918
Drug: Screening and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Screening and treatment for intestinal parasite infection
Trial: 4916790
Drug: Prednisone (20-30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (20-30 mg/24 hours, average 29 mg/24 hours for at least 6 months, with some receiving it for longer)
Trial: 29986146
Drug: Beetroot juice
RxNorm normalized name: tamarind juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beetroot juice (BRJ) supplementation (420 mL, 8.4 mmol inorganic nitrate (NO3‐)·day‐1)
Trial: 25417708
Drug: MP‐376 (levofloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MP‐376 (levofloxacin inhalation solution)
Trial: 23147738
Drug: Intranasal mupirocin
RxNorm normalized name: Mupirocin
DrugBank: Mupirocin (DB00410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal mupirocin (with or without antimicrobial baths)
Trial: 21967362
Drug: Intravenous levetiracetam
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous levetiracetam (2500 mg) with clonazepam (1 mg)
Trial: 21967362
Drug: Clonazepam (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonazepam (1 mg) with placebo
Trial: 15063564
Drug: Tetravalent acellular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetravalent acellular pertussis combined vaccine (DTacP-IPV; Tetravac) as second booster
Trial: 15063564
Drug: Pentavalent two-component
RxNorm normalized name: thrombin
DrugBank: Thrombin (DB11300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentavalent two-component acellular pertussis combined vaccine (DTacP-IPV-Hib; Pentavac)
Trial: 9696501
Drug: Lipiodol chemoembolization
RxNorm normalized name: doxorubicin hydrochloride liposome Injection [LipoDox]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipiodol chemoembolization plus tamoxifen (40 mg)